Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIBC-II: 2-iminobiotin versus standard care in neonates with perinatal asphyxia
PACTR202308870380725Phase 2Recruiting
- Sponsor
- University of Kinshasa Hospital
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of 2-iminobiotin in asphyxia neonatorum and hypoxic-ischemic encephalopathy (HIE) (2 arms), sponsored by University of Kinshasa Hospital. Primary endpoint: Efficacy - survival with normal aEEG at 36 hours. Started Sep 2023; status: recruiting.
02
Drugs
2-iminobiotin
03
Conditions
asphyxia neonatorumhypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on PACTR202308870380725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202308870380725.